SAMe Trial for Patients With Alcoholic Cirrhosis

Alcoholic Cirrhosis Clinical Trial

Official title:

A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04250259
• Other study ID #: SAMe Trial
• Secondary ID: 5U01AA026817-04
• Status: Recruiting
• Phase: Phase 2
• Start date: October 22, 2020
• Est. completion date: September 1, 2025

Study information

• Verified date: October 2023
• Source: Indiana University
• Contact: Kristina Chandler, BS
• Phone: (317) 988-4733
• Email: krimhick[@]iu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 196
• Est. completion date: September 1, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria for patients with alcoholic cirrhosis

1. Evidence of cirrhosis as per clinical signs and/or noninvasive transient elastography (Fibroscan®), computed tomography, magnetic resonance imaging including MRI elastography compatible with cirrhosis and/or histopathology by biopsy and

2. subjects with clinical presentation either in Child Class A or B at the time of enrollment

3. individuals 18 to 70 years old and may or may not consume alcohol during study.

Inclusion criteria for healthy control :

) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink < 50 grams per day on average in women and < 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions.

Exclusion criteria for patients with alcoholic cirrhosis

1. Active infection as evidenced by positive urine culture, blood culture, or pneumonia,

2. Known co-existing infection with hepatitis C, hepatitis B, or HIV

3. Significant systemic or major illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study

4. Gastrointestinal bleeding within the prior 28 days3

5. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening

6. Women who are pregnant, may become pregnant, or nursing

7. Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of SAMe such as those with gastric bypass surgery

8. Subjects with history of/diagnosis of hepatocellular carcinoma

9. Members from the same family of study participant. This is based on the recent paper on the non-random sampling in randomized controlled trials4. We acknowledge that if we assign family members to identical treatment, randomization would not be totally correct; but if properly randomized, there is a chance that the members of the family might mix the pills. To avoid this issue and maintain the integrity of randomized blinded fashion, we will not include members from the same family into the study

10. Subjects with psychiatric illnesses such as bipolar disorders as SAMe may interfere with the levels of anti-psychotic drugs and

11. Subjects who are immunocompromised

Exclusion criteria for all healthy control participants:

1. subjects with an active and serious medical disease

2. subjects with an infectious disease

3. consume any alcohol within 3 months before the study

4. subjects with localized or systemic infection

Related Conditions & MeSH terms

• Alcoholic Cirrhosis
• Fibrosis
• Liver Cirrhosis
• Liver Cirrhosis, Alcoholic

Intervention

Drug:
• Placebo
2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
• SAMe 400 mg tablet
SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months

Locations

Country	Name	City	State
United States	Indiana University Hospital	Indianapolis	Indiana
United States	Cedars-Sinai Medical Center	Los Angeles	California

Sponsors (3)

Lead Sponsor	Collaborator
Indiana University	Cedars-Sinai Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory outcome - identify who will improve their liver functions by taking the SAMe supplement amongst those that have been diagnosed with alcoholic cirrhosis (Child-Pugh score of A or B).	The metabolic profiling of the serum and urine will be collected by those in the study who received the SAMe supplement and will be used as the surrogates for this prediction.	baseline to 24 months
Primary	SAMe supplement's effect on all-cause mortality	The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.	Baseline to end of 24 months
Secondary	SAMe supplement's effect on intestinal permeability function, as defined by serum lipopolysaccharides (LPS)	The function of intestinal permeability will be evaluated by testing serum lipopolysaccharides (LPS) in patients who receive SAMe compared to those who receive placebo. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.	baseline to end of 24 months
Secondary	SAMe supplement's effect on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by mitochondrial DNA	Cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of mitochondrial DNA in the blood of patients who receive SAMe compared to those who receive placebo.	baseline to 24 months
Secondary	SAMe supplement's effect on liver deuteriation	determining Proportion of subjects undergoing liver transplantation in patients who receive SAMe compared to those who receive placebo	baseline to 24 months
Secondary	SAMe supplement's effect on liver developing cancer	Proportion of subjects developing new onset hepatocellular carcinoma in patients who receive SAMe compared to those who receive placebo	baseline to 24 months
Secondary	SAMe supplement's effect on infections of the liver	Proportion of subjects with infection/sepsis (other than SBP) in patients who receive SAMe compared to those who receive placebo	baseline to 24 months
Secondary	SAMe supplement's effect on other parts of the body	capture safety-related endpoints by determining proportion of patients with nausea and emesis, proportion of subjects with unexplained diarrhea in patients receive SAMe compared to those who receive placebo.	baseline to 24 months
Secondary	SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD14	The function of intestinal permeability will be evaluated by testing soluble(s) CD14 in patients who receive SAMe compared to those who receive placebo. sCD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).	baseline to 24 months
Secondary	SAMe supplement's effects on intestinal permeability function, as defined by soluble(s) CD163	The function of intestinal permeability will be evaluated by testing soluble(s) CD163 in patients who receive SAMe compared to those who receive placebo. CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163).	baseline to 24 months
Secondary	SAMe supplement's effects on cellular oxidative stress and/or endoplasmic reticulum (ER) stress, as defined by cytochrome P450 2E1 levels	Levels of cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of cytochrome P450 2E1 (CYP2E1) enriched microparticles in patients who receive SAMe compared to those who receive placebo.CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.	baseline to 24 months